124 related articles for article (PubMed ID: 29992558)
1. Somatic mutations in specific and connected subpathways are associated with short neuroblastoma patients' survival and indicate proteins targetable at onset of disease.
Esposito MR; Binatti A; Pantile M; Coppe A; Mazzocco K; Longo L; Capasso M; Lasorsa VA; Luksch R; Bortoluzzi S; Tonini GP
Int J Cancer; 2018 Nov; 143(10):2525-2536. PubMed ID: 29992558
[TBL] [Abstract][Full Text] [Related]
2. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.
Lasorsa VA; Formicola D; Pignataro P; Cimmino F; Calabrese FM; Mora J; Esposito MR; Pantile M; Zanon C; De Mariano M; Longo L; Hogarty MD; de Torres C; Tonini GP; Iolascon A; Capasso M
Oncotarget; 2016 Apr; 7(16):21840-52. PubMed ID: 27009842
[TBL] [Abstract][Full Text] [Related]
3. Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma.
Bellini A; Bessoltane-Bentahar N; Bhalshankar J; Clement N; Raynal V; Baulande S; Bernard V; Danzon A; Chicard M; Colmet-Daage L; Pierron G; Le Roux L; Planchon JM; Combaret V; Lapouble E; Corradini N; Thebaud E; Gambart M; Valteau-Couanet D; Michon J; Louis-Brennetot C; Janoueix-Lerosey I; Defachelles AS; Bourdeaut F; Delattre O; Schleiermacher G
Int J Cancer; 2019 Nov; 145(10):2781-2791. PubMed ID: 31018240
[TBL] [Abstract][Full Text] [Related]
4. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
5. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
6. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.
Cao Y; Jin Y; Yu J; Wang J; Qiu Y; Duan X; Ye Y; Cheng Y; Dong L; Feng X; Wang D; Li Z; Tian X; Wang H; Yan J; Zhao Q
Oncotarget; 2017 Jul; 8(30):49689-49701. PubMed ID: 28591696
[TBL] [Abstract][Full Text] [Related]
8. Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma.
Kong XT; Choi SH; Inoue A; Xu F; Chen T; Takita J; Yokota J; Bessho F; Yanagisawa M; Hanada R; Yamamoto K; Hayashi Y
Cancer Res; 1997 Sep; 57(17):3772-8. PubMed ID: 9288786
[TBL] [Abstract][Full Text] [Related]
9. RNA-Sequencing Combined With Genome-Wide Allele-Specific Expression Patterning Identifies ZNF44 Variants as a Potential New Driver Gene for Pediatric Neuroblastoma.
Sun L; Li X; Tu L; Stucky A; Huang C; Chen X; Cai J; Li SC
Cancer Control; 2023; 30():10732748231175017. PubMed ID: 37161925
[TBL] [Abstract][Full Text] [Related]
10. Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.
Fransson S; Martinez-Monleon A; Johansson M; Sjöberg RM; Björklund C; Ljungman G; Ek T; Kogner P; Martinsson T
Sci Rep; 2020 Dec; 10(1):22432. PubMed ID: 33384420
[TBL] [Abstract][Full Text] [Related]
11. Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway.
Li Y; Ohira M; Zhou Y; Xiong T; Luo W; Yang C; Li X; Gao Z; Zhou R; Nakamura Y; Kamijo T; Kaneko Y; Taketani T; Ueyama J; Tajiri T; Zhang H; Wang J; Yang H; Yin Y; Nakagawara A
Oncotarget; 2017 Aug; 8(34):56684-56697. PubMed ID: 28915622
[TBL] [Abstract][Full Text] [Related]
12. MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.
Perfumo C; Parodi S; Mazzocco K; Defferrari R; Inga A; Scarrà GB; Ghiorzo P; Haupt R; Tonini GP; Fronza G
Pediatr Blood Cancer; 2009 Oct; 53(4):576-83. PubMed ID: 19526525
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.
Burgues O; Navarro S; Noguera R; Pellín A; Ruiz A; Castel V; Llombart-Bosch A
Virchows Arch; 2006 Oct; 449(4):410-20. PubMed ID: 16941154
[TBL] [Abstract][Full Text] [Related]
14. The mTOR signaling pathway in pediatric neuroblastoma.
Mei H; Wang Y; Lin Z; Tong Q
Pediatr Hematol Oncol; 2013 Oct; 30(7):605-15. PubMed ID: 23697980
[TBL] [Abstract][Full Text] [Related]
15. GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma.
Gumy-Pause F; Pardo B; Khoshbeen-Boudal M; Ansari M; Gayet-Ageron A; Sappino AP; Attiyeh EF; Ozsahin H
Genes Chromosomes Cancer; 2012 Feb; 51(2):174-85. PubMed ID: 22045684
[TBL] [Abstract][Full Text] [Related]
16. Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells.
Coco S; Defferrari R; Scaruffi P; Cavazzana A; Di Cristofano C; Longo L; Mazzocco K; Perri P; Gambini C; Moretti S; Bonassi S; Tonini GP
J Pathol; 2005 Nov; 207(3):346-57. PubMed ID: 16178058
[TBL] [Abstract][Full Text] [Related]
17. Boolean modeling identifies Greatwall/MASTL as an important regulator in the AURKA network of neuroblastoma.
Dahlhaus M; Burkovski A; Hertwig F; Mussel C; Volland R; Fischer M; Debatin KM; Kestler HA; Beltinger C
Cancer Lett; 2016 Feb; 371(1):79-89. PubMed ID: 26616283
[TBL] [Abstract][Full Text] [Related]
18. Integration of molecular features with clinical information for predicting outcomes for neuroblastoma patients.
Han Y; Ye X; Wang C; Liu Y; Zhang S; Feng W; Huang K; Zhang J
Biol Direct; 2019 Aug; 14(1):16. PubMed ID: 31443736
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic anaplastic lymphoma kinase (ALK) mutation in neuroblastomas and other pediatric tumors.
Kwon MJ; Choi YL; Sung KW; Kang SY; Park SM; Choi SY; Kim JS; Suh YL
Pathol Res Pract; 2011 Oct; 207(10):634-9. PubMed ID: 21940108
[TBL] [Abstract][Full Text] [Related]
20. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
